Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer

Phase 2

Recruiting

• Conditions: nresectable metastatic or recurrent colorectal cancer

• Registration Number: JPRN-UMIN000011679
• Lead Sponsor: Chubu Clinical Oncology Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-09-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

1)Treatment of TS-1 within a week. 2)Patient who had treatment including irinotecan. 3)Uncontrolled infection. 4)Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated 5)Previous history of thoromboembolitic disease,or necessity for antithrombotic drug. 6)Severe lung disease.(Interstitial lung disease or pulmonary fibrosis.) 7)Severe liver disease. 8)Severe renal failure. 9)Previous history of severe drug-induced allergy 10)Intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. 11)History of gastrointestinal perforation within 1 year. 12)Uncontrolled severe complications(DM, hypertension, diarrhea, et al.) 13)History of active double cancer. 14)Massive pleural effusion or ascites that required drainage. 15)Brain metastasis 16)Patients with psycho-neurological disease,central nervous system damage,cerebrovascular disorder 17)Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week. 18)Patient with untreated traumatic bone fracture. 19)Diathesis of bleeding (history of hemoptysis,including cavitation and/or necrosis in lung metastasis confirmed by imaging),coagulopathy. 20) Systemic administration of antiplatelet drug 21)Administration of immunosuppressants associated with organ transplantation 22)Patient who have peripheral nerve disorder 23)Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers. 24)Not appropriate for the study at the physician's assessment

Study & Design

• Study Type: Interventional
• Study Design: Not specified